Evaluation of QOL in children with short stature after initiation of growth hormone therapy.

Evaluation of QOL in children with short stature after initiation of growth hormone therapy. - GT-QOL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026570

Enrollment

100

Registered

2017-03-15

Start date

2016-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small stature caused by growth hormone deficiency, Turner syndrome, or small for gestational age

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children with short stature caused by -growth hormone deficiency -Turner syndrome -small for gestational age whose epiphyseal growth plates remain unclosed. -Never received growth hormone therapy before. -Written informed consent.

Exclusion criteria

Exclusion criteria: -Contraindication for Growject -Patients (or parents) who are not supposed to be able to answer the questionnaire appropriately. -Judgement of physicians.

Design outcomes

Primary

Measure	Time frame
Evaluation of QOL after 6 months and 12 months of growth hormone therapy compared with pretreatment.	—

Secondary

Measure	Time frame
-Comparison of QOL of patients with that of normal children. -Comparison of QOL measured by parents with that by patients themselves who are supposed to be able to answer the questionnaire.	—

Countries

Japan

Contacts

Public ContactShinobu Ida

Osaka Women's and Children's Hospital Department of Pediatric Gastroenterology and Endocrinology

idas@wch.opho.jp0725-56-1220

Outcome results